Two anti-FGFR therapies have recently been approved by the Food and Drug Administration (FDA), including erdafitinib for FGFR3-altered urothelial cancer and pemigatinib for FGFR2-fusion cholangiocarcinoma.10,11 While the majority of patients are initially sensitive to FGFR-targeted therapies, many develop acquired resistance ultimately resulting in disease progression and discontinuation of therapy. The gene discussed is FGFR2; the disease is cholangiocarcinoma.